<p>MBX Biosciences, Inc. (NASDAQ:MBX - 获取免费报告) 在一月份的空头头寸出现了大幅下降。截至 1 月 15 日，空头头寸总计为 2,307,824 股，较 12 月 31 日的 3,843,943 股下降了 40.0%。大约 5.1% 的公司股票被做空。根据每日平均交易量 800,131 股，当前的空头头寸比率为 2.9 天。根据每日平均交易量 800,131 股，当前的空头头寸比率为 2.9 天。大约 5.1% 的公司股票被做空。</p>
<p>获取 <strong>MBX Biosciences</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>MBX 最近成为几份分析师报告的主题。Weiss Ratings 在 1 月 22 日的报告中重申了对 MBX Biosciences 股票的 &#34;卖出 (d-)&#34; 评级。Stifel Nicolaus 在 12 月 19 日的研究报告中将 MBX Biosciences 的目标价从 45.00 美元上调至 50.00 美元，并给予该公司 &#34;买入&#34; 评级。高盛集团在 12 月 4 日的报告中开始覆盖 MBX Biosciences，设定了 &#34;卖出&#34; 评级和 18.00 美元的目标价。TD Cowen 在 11 月 4 日的研究报告中开始覆盖 MBX Biosciences 股票，给予该公司 &#34;买入&#34; 评级。最后，Guggenheim 在 1 月 16 日的研究报告中将 MBX Biosciences 股票的目标价从 77.00 美元上调至 88.00 美元，并给予该股票 &#34;买入&#34; 评级。十一位投资分析师对该股票给予了买入评级，两个分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 &#34;适度买入&#34;，平均目标价为 50.20 美元。</p>
<p><strong>阅读我们关于 MBX Biosciences 的最新报告</strong></p>
<h2>机构资金流入和流出</h2>
<p>几家大型投资者最近买入和卖出了该公司的股票。TD Asset Management Inc 在第二季度将其在 MBX Biosciences 的持股增加了 13.1%。TD Asset Management Inc 目前拥有 171,304 股公司股票，价值 1,955,000 美元，在上个季度购买了额外的 19,800 股。Koa Wealth Management LLC 在第二季度将其在 MBX Biosciences 的持股增加了 63.7%。Koa Wealth Management LLC 目前拥有 31,752 股公司股票，价值 362,000 美元，在此期间购买了额外的 12,356 股。Geode Capital Management LLC 在第二季度将其在 MBX Biosciences 的持股增加了 27.0%。Geode Capital Management LLC 目前拥有 348,447 股公司股票，价值 3,976,000 美元，在上个季度购买了额外的 73,989 股。Intech Investment Management LLC 在第二季度将其在 MBX Biosciences 的持股增加了 33.0%。Intech Investment Management LLC 目前拥有 14,271 股公司股票，价值 163,000 美元，在上个季度获得了额外的 3,543 股。最后，洛克菲勒资本管理公司在第二季度收购了 MBX Biosciences 的新股份，价值约 389,000 美元。</p>
<h2>MBX Biosciences 股票表现</h2>
<p>MBX 股票在周五开盘价为 36.62 美元。该股票的市值为 16.4 亿美元，市盈率为-15.32，贝塔值为 0.86。MBX Biosciences 的 12 个月最低价为 4.81 美元，最高价为 44.89 美元。该公司的 50 日简单移动平均线为 33.26 美元。</p>
<p>MBX Biosciences (NASDAQ:MBX - 获取免费报告) 最近在 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为（0.63 美元），超出市场共识预期的（0.73 美元）0.10 美元。</p>
<h2>MBX Biosciences 公司简介</h2>
<p>(获取免费报告)</p>
<p>我们是一家临床阶段的生物制药公司，专注于新型精准肽疗法的发现和开发，以治疗内分泌和代谢疾病。我们的公司由全球领先的专家创立，采用变革性的方法进行肽药物设计和开发。利用这一专业知识，我们设计了专有的精准内分泌肽™（PEPTM）平台，以克服未修饰和修饰肽疗法的关键局限性，并改善临床结果，简化患者的疾病管理。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票，胜过 MBX Biosciences</li>
<li>美国第一混乱交易者：“我非常看涨”</li>
<li>特朗普的新行政命令 - 退休账户将迎来重大变化</li>
<li>新银行法 #1582 可能为美国人解锁 21 万亿美元</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 MBX Biosciences 吗？</h2>
<p>在你考虑 MBX Biosciences 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入... 而 MBX Biosciences 并不在名单上。</p>
<p>虽然 MBX Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>查看这五只股票</p>

IBBQ

动态生物技术与基因组 ETF - Invesco

生物科技 ETF - VanEck Vectors

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

基因改革 ETF - ARK

医药突破 ETF - ALPS

<p>MBX Biosciences, Inc.（纳斯达克代码：MBX）在 1 月 15 日的空头头寸显著下降，减少了 40%，降至 2,307,824 股。目前，该股票的空头比例为 5.1%，覆盖天数比率为 2.9 天。分析师的评级意见不一，Weiss Ratings 给予 “卖出（d-）” 评级，而 Stifel Nicolaus 将目标股价上调至 50.00 美元。该股票开盘价为 36.62 美元，市值为 16.4 亿美元，市盈率为-15.32。该公司专注于开发用于内分泌和代谢疾病的精准肽疗法</p>

<p>MBX Biosciences, Inc. (NASDAQ:MBX - Get Free Report) was the target of a large drop in short interest in the month of January. As of January 15th, there was short interest totaling 2,307,824 shares, a drop of 40.0% from the December 31st total of 3,843,943 shares. Approximately 5.1% of the company's stock are short sold. Based on an average daily volume of 800,131 shares, the short-interest ratio is currently 2.9 days. Based on an average daily volume of 800,131 shares, the short-interest ratio is currently 2.9 days. Approximately 5.1% of the company's stock are short sold.</p>
<div class="lb-trans"><p>MBX Biosciences, Inc. (NASDAQ:MBX - 获取免费报告) 在一月份的空头头寸出现了大幅下降。截至 1 月 15 日，空头头寸总计为 2,307,824 股，较 12 月 31 日的 3,843,943 股下降了 40.0%。大约 5.1% 的公司股票被做空。根据每日平均交易量 800,131 股，当前的空头头寸比率为 2.9 天。根据每日平均交易量 800,131 股，当前的空头头寸比率为 2.9 天。大约 5.1% 的公司股票被做空。</p>
</div><p>Get <strong>MBX Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>MBX Biosciences</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>MBX has been the subject of several analyst reports. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of MBX Biosciences in a report on Thursday, January 22nd. Stifel Nicolaus boosted their price target on MBX Biosciences from $45.00 to $50.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, December 19th. The Goldman Sachs Group initiated coverage on MBX Biosciences in a report on Thursday, December 4th. They set a &#34;sell&#34; rating and a $18.00 target price for the company. TD Cowen began coverage on shares of MBX Biosciences in a research report on Tuesday, November 4th. They set a &#34;buy&#34; rating for the company. Finally, Guggenheim increased their price objective on shares of MBX Biosciences from $77.00 to $88.00 and gave the stock a &#34;buy&#34; rating in a research note on Friday, January 16th. Eleven investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of &#34;Moderate Buy&#34; and an average price target of $50.20.</p>
<div class="lb-trans"><p>MBX 最近成为几份分析师报告的主题。Weiss Ratings 在 1 月 22 日的报告中重申了对 MBX Biosciences 股票的 &#34;卖出 (d-)&#34; 评级。Stifel Nicolaus 在 12 月 19 日的研究报告中将 MBX Biosciences 的目标价从 45.00 美元上调至 50.00 美元，并给予该公司 &#34;买入&#34; 评级。高盛集团在 12 月 4 日的报告中开始覆盖 MBX Biosciences，设定了 &#34;卖出&#34; 评级和 18.00 美元的目标价。TD Cowen 在 11 月 4 日的研究报告中开始覆盖 MBX Biosciences 股票，给予该公司 &#34;买入&#34; 评级。最后，Guggenheim 在 1 月 16 日的研究报告中将 MBX Biosciences 股票的目标价从 77.00 美元上调至 88.00 美元，并给予该股票 &#34;买入&#34; 评级。十一位投资分析师对该股票给予了买入评级，两个分析师给予了卖出评级。根据 MarketBeat.com 的数据，该股票的平均评级为 &#34;适度买入&#34;，平均目标价为 50.20 美元。</p>
</div><p><strong>Read Our Latest Report on MBX Biosciences</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 MBX Biosciences 的最新报告</strong></p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Several large investors have recently bought and sold shares of the business. TD Asset Management Inc boosted its position in shares of MBX Biosciences by 13.1% during the 2nd quarter. TD Asset Management Inc now owns 171,304 shares of the company's stock worth $1,955,000 after purchasing an additional 19,800 shares in the last quarter. Koa Wealth Management LLC grew its position in MBX Biosciences by 63.7% during the second quarter. Koa Wealth Management LLC now owns 31,752 shares of the company's stock worth $362,000 after buying an additional 12,356 shares during the period. Geode Capital Management LLC increased its holdings in MBX Biosciences by 27.0% in the second quarter. Geode Capital Management LLC now owns 348,447 shares of the company's stock valued at $3,976,000 after buying an additional 73,989 shares in the last quarter. Intech Investment Management LLC boosted its stake in shares of MBX Biosciences by 33.0% during the 2nd quarter. Intech Investment Management LLC now owns 14,271 shares of the company's stock worth $163,000 after acquiring an additional 3,543 shares in the last quarter. Finally, Rockefeller Capital Management L.P. acquired a new stake in shares of MBX Biosciences in the 2nd quarter worth approximately $389,000.</p>
<div class="lb-trans"><p>几家大型投资者最近买入和卖出了该公司的股票。TD Asset Management Inc 在第二季度将其在 MBX Biosciences 的持股增加了 13.1%。TD Asset Management Inc 目前拥有 171,304 股公司股票，价值 1,955,000 美元，在上个季度购买了额外的 19,800 股。Koa Wealth Management LLC 在第二季度将其在 MBX Biosciences 的持股增加了 63.7%。Koa Wealth Management LLC 目前拥有 31,752 股公司股票，价值 362,000 美元，在此期间购买了额外的 12,356 股。Geode Capital Management LLC 在第二季度将其在 MBX Biosciences 的持股增加了 27.0%。Geode Capital Management LLC 目前拥有 348,447 股公司股票，价值 3,976,000 美元，在上个季度购买了额外的 73,989 股。Intech Investment Management LLC 在第二季度将其在 MBX Biosciences 的持股增加了 33.0%。Intech Investment Management LLC 目前拥有 14,271 股公司股票，价值 163,000 美元，在上个季度获得了额外的 3,543 股。最后，洛克菲勒资本管理公司在第二季度收购了 MBX Biosciences 的新股份，价值约 389,000 美元。</p>
</div><h2>MBX Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>MBX Biosciences 股票表现</h2>
</div><p>MBX stock opened at $36.62 on Friday. The stock has a market cap of $1.64 billion, a P/E ratio of -15.32 and a beta of 0.86. MBX Biosciences has a 12 month low of $4.81 and a 12 month high of $44.89. The firm has a fifty day simple moving average of $33.26.</p>
<div class="lb-trans"><p>MBX 股票在周五开盘价为 36.62 美元。该股票的市值为 16.4 亿美元，市盈率为-15.32，贝塔值为 0.86。MBX Biosciences 的 12 个月最低价为 4.81 美元，最高价为 44.89 美元。该公司的 50 日简单移动平均线为 33.26 美元。</p>
</div><p>MBX Biosciences (NASDAQ:MBX - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.73) by $0.10.</p>
<div class="lb-trans"><p>MBX Biosciences (NASDAQ:MBX - 获取免费报告) 最近在 11 月 6 日发布了季度财报。该公司报告每股收益（EPS）为（0.63 美元），超出市场共识预期的（0.73 美元）0.10 美元。</p>
</div><h2>MBX Biosciences Company Profile</h2>
<div class="lb-trans"><h2>MBX Biosciences 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.</p>
<div class="lb-trans"><p>我们是一家临床阶段的生物制药公司，专注于新型精准肽疗法的发现和开发，以治疗内分泌和代谢疾病。我们的公司由全球领先的专家创立，采用变革性的方法进行肽药物设计和开发。利用这一专业知识，我们设计了专有的精准内分泌肽™（PEPTM）平台，以克服未修饰和修饰肽疗法的关键局限性，并改善临床结果，简化患者的疾病管理。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than MBX Biosciences</li>
<li>America’s #1 Chaos Trader: “I’m so #&amp;!$ bullish”</li>
<li>Trump's NEW Executive Order - BIG Changes Coming to Retirement Accounts</li>
<li>New Banking Law #1582 Could Unlock $21 Trillion for Americans</li>
<li>Refund From 1933: Trump’s Reset May Create Instant Wealth</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 MBX Biosciences</li>
<li>美国第一混乱交易者：“我非常看涨”</li>
<li>特朗普的新行政命令 - 退休账户将迎来重大变化</li>
<li>新银行法 #1582 可能为美国人解锁 21 万亿美元</li>
<li>1933 年的退款：特朗普的重置可能创造即时财富</li>
<li>崩盘已经开始（大多数人只是还没看到）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in MBX Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 MBX Biosciences 吗？</h2>
</div><p>Before you consider MBX Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 MBX Biosciences 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入... 而 MBX Biosciences 并不在名单上。</p>
</div><p>While MBX Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MBX Biosciences 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

MBX Biosciences, Inc. (NASDAQ:MBX) 空头头寸最新动态